Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:

• Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLC
• Long-term safety observations for crizotinib and entrectinib 
• CNS activity of entrectinib and repotrectinib in patients with brain metastases
• Repotrectinib activity in ROS1-TKI resistance mutations 
   

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:
To download the slides associated with this podcast discussion, please visit the program page.